Migraine: Preventive Treatment

Current Medical Research and Opinion

Volumn 17, Issue sup1, 2001, Pages s87-93

  Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Aes; Antidepressants; Beta blockers; Migraine prevention

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; MONOAMINE OXIDASE INHIBITOR; RIBOFLAVIN; SEROTONIN ANTAGONIST;

HUMAN; MIGRAINE; PHYTOTHERAPY; REVIEW; TANACETUM PARTHENIUM;

ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; MIGRAINE DISORDERS; MONOAMINE OXIDASE INHIBITORS; PHYTOTHERAPY; RIBOFLAVIN; SEROTONIN ANTAGONISTS; TANACETUM PARTHENIUM;

EID: 0035752526     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/0300799039117007     Document Type: Article

References (40)

1. Silberstein SD, Saper JR, Freitag F. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff’s Headache and other Head Pain, 7th edn. New York: Oxford University Press, 2001
2. Silberstein SD. Practice parameter – evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology 2000; 55: 754 – 62
3. Tfelt-Hansen P. Prioritizing acute pharmacotherapy of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 2nd edn. New York: Lippincott Williams & Wilkins, 2000: 453 – 6
4. Gray RN, Goslin RE, McCrory DC, et al. Drug Treatments for the Prevention of Migraine Headache, 1999. Agency for Health Care Policy and Research Contract No. 290-94-2025 National Technical Information Service Accession No. 127953
5. Andersson K, Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990; 39: 355 – 73
6. Couch JR, Ziegler D, Hassanein R. Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976; 26: 121 – 7
7. Feinmann C. Pain relief by antidepressants: possible modes of action. Pain 1985; 23: 1 – 8
8. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 1990; 65: 1227 – 36
9. Richardson JW, Richelson E. Antidepressants: a clinical update for medical practitioners. Mayo Clin Proc 1984; 59: 330 – 7
10. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics, 8th edn. New York: Pergamon, 1990: 383 – 435
11. Abramowicz M. Fluoxetine (Prozac) revisited. Drugs Ther 1990;Medical Letter: 83 – 5
12. Barnhart ER. Physicians’ Desk Reference, 45th edn. Oradell: Medical Economics, 1991
13. Lance JW. The pharmacotherapy of migraine. Med J Aust 1986; 144: 85 – 8
14. Tollefson GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry 1983; 44: 280 – 8
15. Clary C, Schweitzer E. The treatment of MAOI hypertensive crisis with sublingual nifedipine. Clin Psychiatry 1987; 48: 249 – 50
16. Greenberg DA. Calcium channels in neurological disease. Ann Neurol 1997; 42: 275 – 82
17. Varadi G, Mori Y, Mikala G, Schwartz A. Molecular determinants of Ca2+ channel function and drug action. TiPS 1995; 2: 43 – 9
18. Ophoff RA, Terwindt GM, Vergouwe MN. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLA4. Cell Tiss Res 1996; 87: 543 – 52
19. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol Rev 1990; 42: 223 – 86
20. Silberstein SD, Collins SD, Carlson H, Depakote ER. Migraine Study Group. Safety and efficacy of once-daily, extended-release divalproex sodium monotherapy for the prophylaxis of migraine headaches. Cephalalgia 2000;20: 269. (Abstract)
21. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the long-term safety of depakote in headache prophylaxis study group). Headache 1999; 39: 633 – 43
22. Mathew NT. Gabapentin in migraine prophylaxis. Cephalalgia 1996; 16: 367
23. Wessely P, Baumgartner C, Klinger D, et al. Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. Cephalalgia 1987; 7: 477 – 8
24. Mathew N, Saper J, Magnus-Miller L. Efficacy and safety of gabapentin (Neurontin®) in migraine prophylaxis. 17th Annual Meeting of the American Pain Society 1998;San Diego, CA (Abstract)
25. Easterling DE, Zakszewski T, Moyer MD. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans. Epilepsia 1988; 29: 662
26. Edwards KR. A double-blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. 18th Annual Scientific Meeting of the American Pain Society, Fort Lauderdale, Florida, October 21st–29th, 1999
27. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of Topamax® (topiramate) in the prophylactic treatment of migraine. Neurology 2000 (in press)
28. Freitag FG, Diamond S, Diamond ML, et al. The prophylaxis of migraine with the GABA-agonist, tiagabine: a clinical report. Headache 1999;19 (Abstract)
29. Sicuteri R. Prophylactic and therapeutic properties of 1-methylsergic acid butanolamide in migraine. Int Arch Allerg 1959; 15: 300 – 7
30. Silberstein SD. Methysergide. Cephalalgia 1998; 18: 421 – 35
31. Forsythe I, Hockaday JM. Management of childhood migraine. In: Hockaday JM, ed. Migraine in Childhood. London: Butterworths, 1988: 63 – 74
32. Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry 1964; 27: 463 – 9
33. Peatfield R. Drugs acting by modification of serotonin function. Headache 1986; 26: 129 – 31
34. Capildeo R, Rose FC. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. Headache 1982; 22: 272 – 5
35. Palevitch D, Earon G, Carusso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997; 11: 508 – 11
36. Deweerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of feverfew preparation. Phytomedicine 1996; 3: 225 – 30
37. Welch KMA, Levine SRDG, Schultz L, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31phosphorus NMR spectroscopy. Neurology 1989; 39: 538 – 41
38. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466 – 70
39. Silberstein SD, Lipton RB, Goadsby PJ. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Goadsby PJ, eds. Headache in Clinical Practice, 1st edn. Oxford: Isis Medical Media, 1998: 61 – 90
40. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1997; 17: 67 – 72